These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. 3D-QSAR studies on triclosan derivatives as Plasmodium falciparum enoyl acyl carrier reductase inhibitors. Shah P; Siddiqi MI SAR QSAR Environ Res; 2010 Jul; 21(5-6):527-45. PubMed ID: 20818586 [TBL] [Abstract][Full Text] [Related]
24. Homology modeling of wild type and pyrimethamine/cycloguanil-cross resistant mutant type Plasmodium falciparum dihydrofolate reductase. A model for antimalarial chemotherapy resistance. Santos-Filho OA; de Alencastro RB; Figueroa-Villar JD Biophys Chem; 2001 Jul; 91(3):305-17. PubMed ID: 11551441 [TBL] [Abstract][Full Text] [Related]
25. Quantitative structure activity relationship study of 2,4,6-trisubstituted-s-triazine derivatives as antimalarial inhibitors of Plasmodium falciparum dihydrofolate reductase. Ojha H; Gahlot P; Tiwari AK; Pathak M; Kakkar R Chem Biol Drug Des; 2011 Jan; 77(1):57-62. PubMed ID: 20958921 [TBL] [Abstract][Full Text] [Related]
27. A novel Plasmodium falciparum expression system for assessing antifolate resistance caused by mutant P. vivax dihydrofolate reductase-thymidylate synthase. O'Neil MT; Korsinczky ML; Gresty KJ; Auliff A; Cheng Q J Infect Dis; 2007 Aug; 196(3):467-74. PubMed ID: 17597462 [TBL] [Abstract][Full Text] [Related]
28. QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. Hou X; Chen X; Zhang M; Yan A SAR QSAR Environ Res; 2016; 27(2):101-24. PubMed ID: 26911561 [TBL] [Abstract][Full Text] [Related]
29. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Cortese JF; Plowe CV Mol Biochem Parasitol; 1998 Aug; 94(2):205-14. PubMed ID: 9747971 [TBL] [Abstract][Full Text] [Related]
30. QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives. Hecht D; Cheung M; Fogel GB Biosystems; 2008 Apr; 92(1):10-5. PubMed ID: 18160210 [TBL] [Abstract][Full Text] [Related]
31. Plasmodium falciparum: mutation pattern in the dihydrofolate reductase-thymidylate synthase genes of Vietnamese isolates, a novel mutation, and coexistence of two clones in a Thai patient. Zindrou S; Nguyen PD; Nguyen DS; Sköld O; Swedberg G Exp Parasitol; 1996 Oct; 84(1):56-64. PubMed ID: 8888732 [TBL] [Abstract][Full Text] [Related]
33. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Fidock DA; Nomura T; Wellems TE Mol Pharmacol; 1998 Dec; 54(6):1140-7. PubMed ID: 9855645 [TBL] [Abstract][Full Text] [Related]
34. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Fidock DA; Wellems TE Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10931-6. PubMed ID: 9380737 [TBL] [Abstract][Full Text] [Related]
35. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum. Kumari M; Chandra S; Tiwari N; Subbarao N BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744 [TBL] [Abstract][Full Text] [Related]
36. Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene. Zindrou S; Dao LD; Xuyen PT; Dung NP; Sy ND; Skold O; Swedberg G Am J Trop Med Hyg; 1996 Feb; 54(2):185-8. PubMed ID: 8619445 [TBL] [Abstract][Full Text] [Related]
37. Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors. Yuthavong Y; Yuvaniyama J; Chitnumsub P; Vanichtanankul J; Chusacultanachai S; Tarnchompoo B; Vilaivan T; Kamchonwongpaisan S Parasitology; 2005 Mar; 130(Pt 3):249-59. PubMed ID: 15796007 [TBL] [Abstract][Full Text] [Related]
38. Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. McKie JH; Douglas KT; Chan C; Roser SA; Yates R; Read M; Hyde JE; Dascombe MJ; Yuthavong Y; Sirawaraporn W J Med Chem; 1998 Apr; 41(9):1367-70. PubMed ID: 9554869 [TBL] [Abstract][Full Text] [Related]
39. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance. Rastelli G; Sirawaraporn W; Sompornpisut P; Vilaivan T; Kamchonwongpaisan S; Quarrell R; Lowe G; Thebtaranonth Y; Yuthavong Y Bioorg Med Chem; 2000 May; 8(5):1117-28. PubMed ID: 10882022 [TBL] [Abstract][Full Text] [Related]
40. Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition. Adane L; Patel DS; Bharatam PV Chem Biol Drug Des; 2010 Jan; 75(1):115-26. PubMed ID: 19895504 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]